Multiple Myeloma Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewMultiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. The American Cancer Society estimates that 20,580 new cases of MM will occur in the United States in 2009, including 11,680 in men and 8900 in women, with an estimated 10,580 deaths.1 The mean age of affected individuals is 62 years for men (75% > 70 years) and 61 years for women (79% > 70 years). The treatment of MM has dramatically improved over the past decade. The 5-year survival rate reported in the Surveillance Epidemiology and End Results database has increased from 25% in 1975 to 34% in 2003 because of the availability of newer and more effective treatment options.2,3MM is typically sensitive to various cytotoxic drugs, both as initial treatment...
If the inline PDF is not rendering correctly, you can download the PDF file here.
DewaldGW, TherneauT, LarsonD. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood2005;106:3553–3558.
DewaldGWTherneauTLarsonD. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood2005;106:3553–3558.
)| false
SchirrmeisterH, BommerM, BuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361–366.
SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361–366.
)| false
DispenzieriA, KyleR, MerliniG. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia2009;23:215–224.
DispenzieriAKyleRMerliniG. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia2009;23:215–224.
)| false
GreippP, LustJ, O’FallonM. Plasma cell labeling index and B2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood1993;81:3382–3387.
GreippPLustJO’FallonM. Plasma cell labeling index and B2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood1993;81:3382–3387.
)| false
KnowlingMA, HarwoodAR, BergsagelDE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol1983;1:255–262.
KnowlingMAHarwoodARBergsagelDE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol1983;1:255–262.
)| false
KatoT, TsukamotoE, NishiokaT. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med2000;25:870–873.
KatoTTsukamotoENishiokaT. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med2000;25:870–873.
)| false
SchirrmeisterH, BommerM, BuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361–366.
SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361–366.
)| false
OrchardK, BarringtonS, BuscombeJ. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol2002;117:133–135.
OrchardKBarringtonSBuscombeJ. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol2002;117:133–135.
)| false
SchirrmeisterH, BuckAK, BergmannL. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm2003;8:841–845.
SchirrmeisterHBuckAKBergmannL. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm2003;8:841–845.
)| false
HarousseauJL, MathiotC, AttalM. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 8505.
HarousseauJLMathiotCAttalM. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 8505.
)| false
SonneveldP, van der HoltB, Schmidt-WolfIGH. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood2008;112:243a. Abstract 653.
SonneveldPvan der HoltBSchmidt-WolfIGH. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood2008;112:243a. Abstract 653.
)| false
CavoM, TacchettiP, PatriarcaF. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood2008;112:Abstract 158.
CavoMTacchettiPPatriarcaF. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood2008;112:Abstract 158.
)| false
RichardsonP, JagannathS, RajeN. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase II study [abstract]. Blood2007;110:Abstract 187.
RichardsonPJagannathSRajeN. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase II study [abstract]. Blood2007;110:Abstract 187.
)| false
RichardsonP, LonialS, JakubowiakA. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Blood2008;112:Abstract 92.
RichardsonPLonialSJakubowiakA. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Blood2008;112:Abstract 92.
)| false
MateosMV, HernandezJM, HernandezMT. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 trial. Blood2006;108:2165–2172.
MateosMVHernandezJMHernandezMT. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 trial. Blood2006;108:2165–2172.
)| false
ZonderAJ, CrowleyJ, HusseinM. Superiority of lenalidomide (Len) plus high-dose Dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract]. Blood2007;110:Abstract 77.
ZonderAJCrowleyJHusseinM. Superiority of lenalidomide (Len) plus high-dose Dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract]. Blood2007;110:Abstract 77.
)| false
RajkumarSV, JacobusS, CallanderN. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2006;108:Abstract 799.
RajkumarSVJacobusSCallanderN. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2006;108:Abstract 799.
)| false
RajkumarSV, JacobusS, CallanderN. Randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2007;110:Abstract 74.
RajkumarSVJacobusSCallanderN. Randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2007;110:Abstract 74.
)| false
ParipatiH, StewartAK, CabouS. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia2008;22:1282–1284.
ParipatiHStewartAKCabouS. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia2008;22:1282–1284.
)| false
KumarS, DispenzieriA, LacyMQ. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia2007;21:2035–2042.
KumarSDispenzieriALacyMQ. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia2007;21:2035–2042.
)| false
RajkumarSV, BloodE, VesoleD. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol2006;24:431–436.
RajkumarSVBloodEVesoleD. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol2006;24:431–436.
)| false
RifkinRM, GregorySA, MohrbacherA, HusseinMA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer2006;106:848–858.
RifkinRMGregorySAMohrbacherAHusseinMA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer2006;106:848–858.
)| false
GregoryWM, RichardsMA, MalpasJS. Combination chemotherapy vs. melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol1992;10:334–342.
GregoryWMRichardsMAMalpasJS. Combination chemotherapy vs. melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol1992;10:334–342.
)| false
PalumboA, BringhenS, CaravitaT. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet2006;367:825–831.
PalumboABringhenSCaravitaT. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet2006;367:825–831.
)| false
FaconT, MaryJY, HulinC. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet2007;370:1209–1218.
FaconTMaryJYHulinC. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet2007;370:1209–1218.
)| false
HulinC, FaconT, RodonP. Melphalan- prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01 [abstract]. Blood2007;110:Abstract 75
HulinCFaconTRodonP. Melphalan- prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01 [abstract]. Blood2007;110:Abstract 75)| false
PalumboA, BringhenS, LiberatiAM. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood2008;112:3107–3114.
PalumboABringhenSLiberatiAM. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood2008;112:3107–3114.
)| false
WijermansP, SchaafsmaM, van NordenY. Melphalan + prednisone versus melphalan + prednisone + thalidomide induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON [abstract]. Haematologica2008;93:Abstract 178.
WijermansPSchaafsmaMvan NordenY. Melphalan + prednisone versus melphalan + prednisone + thalidomide induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON [abstract]. Haematologica2008;93:Abstract 178.
)| false
San MiguelJF, SchlagR, KhuagevaNK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med2008;359:906–917.
San MiguelJFSchlagRKhuagevaNK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med2008;359:906–917.
)| false
MiguelJFS, SchlagR, KhuagevaNK. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma [abstract]. Blood2008;112:Abstract 650.
MiguelJFSSchlagRKhuagevaNK. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma [abstract]. Blood2008;112:Abstract 650.
)| false
BadrosA, BarlogieB, MorrisC. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood2001;97:2574–2579.
BadrosABarlogieBMorrisC. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood2001;97:2574–2579.
)| false
KrogerN, SchwerdtfegerR, KiehlM. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood2002;100:755–760.
KrogerNSchwerdtfegerRKiehlM. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood2002;100:755–760.
)| false
MaloneyD, SahebiF, Stockerl-GoldsteinKE. Combining an allogenic graft versus myeloma effect with high dose autologous stem cell rescue in the treatment of multiple myeloma [abstract]. Blood2001;98:Abstract 434a.
MaloneyDSahebiFStockerl-GoldsteinKE. Combining an allogenic graft versus myeloma effect with high dose autologous stem cell rescue in the treatment of multiple myeloma [abstract]. Blood2001;98:Abstract 434a.
)| false
MoreauP, FaconT, AttalM. Intergroupe Francophone du Myelome. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood2002;99:731–735.
MoreauPFaconTAttalM. Intergroupe Francophone du Myelome. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood2002;99:731–735.
)| false
AttalM, HarousseauJL, StoppaAM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med1996;335:91–97.
AttalMHarousseauJLStoppaAM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med1996;335:91–97.
)| false
ChildJA, MorganGJ, DaviesFE. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med2003;348:1875–1883.
ChildJAMorganGJDaviesFE. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med2003;348:1875–1883.
)| false
BarlogieB, KyleRA, AndersonKC. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma. Final results of phase III US Intergroup Trial S9321. J Clin Oncol2006;24:929–936.
BarlogieBKyleRAAndersonKC. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma. Final results of phase III US Intergroup Trial S9321. J Clin Oncol2006;24:929–936.
)| false
FermandJP, KatsahianS, DivineM. High dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:9227–9233.
FermandJPKatsahianSDivineM. High dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:9227–9233.
)| false
HahnT, WingardJR, AndersonKC. The role of cytotoxic therapy with haematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidenced based review. Biol Blood Marrow Transplant2003;9:4–37.
HahnTWingardJRAndersonKC. The role of cytotoxic therapy with haematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidenced based review. Biol Blood Marrow Transplant2003;9:4–37.
)| false
FermandJP, KatsahianS, DevineM. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:9227–9233.
FermandJPKatsahianSDevineM. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:9227–9233.
)| false
GoldschmidtH. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica2005;90(Suppl 1):Abstract 38.
GoldschmidtH. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica2005;90(Suppl 1):Abstract 38.
)| false
SonneveldP, van der HoltB, SegerenC. Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study HOVON 24 MM [abstract]. Blood2004;104:Abstract 948.
SonneveldPvan der HoltBSegerenC. Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study HOVON 24 MM [abstract]. Blood2004;104:Abstract 948.
)| false
CavoM, TosiP, ZamagniE. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study. J Clin Oncol2007;25:2434–2441.
CavoMTosiPZamagniE. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study. J Clin Oncol2007;25:2434–2441.
)| false
KumarA, LoughranT, AlsinaM. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol2003;4:293–304.
KumarALoughranTAlsinaM. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol2003;4:293–304.
)| false
GarbanF, AttalM, MichalletM. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood2006;107:3474–3480.
GarbanFAttalMMichalletM. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood2006;107:3474–3480.
)| false
MaloneyDG, MolinaAJ, SahebiF. Allografting with nonmyeloablative conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma. Blood2003;102:3447–3454.
MaloneyDGMolinaAJSahebiF. Allografting with nonmyeloablative conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma. Blood2003;102:3447–3454.
)| false
CrawleyC, LalancetteM, SzydloR. Outcome for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood2005;105:4532–4539.
CrawleyCLalancetteMSzydloR. Outcome for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood2005;105:4532–4539.
)| false
BrowmanGP, BergsagelD, SicheriD. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1995;13:2354–2360.
BrowmanGPBergsagelDSicheriD. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1995;13:2354–2360.
)| false
ShustikC, BelchA, RobinsonS. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study: MY.7 [abstract]. J Clin Oncol2004;22(Suppl 14):Abstract 6510.
ShustikCBelchARobinsonS. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study: MY.7 [abstract]. J Clin Oncol2004;22(Suppl 14):Abstract 6510.
)| false
FritzE, LudwigH. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol2000;11:1427–1436.
FritzELudwigH. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol2000;11:1427–1436.
)| false
AttalM, HarousseauJL, LeyvrazS. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood2006;108:3289–3294.
AttalMHarousseauJLLeyvrazS. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood2006;108:3289–3294.
)| false
SpencerA, PrinceM, RobertsAW. First analysis of the Australian leukaemia and lymphoma group (ALLG) trial of thalidomide and alternate day prednisone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLGMM6) [abstract]. Blood2006;108:Abstract 58.
SpencerAPrinceMRobertsAW. First analysis of the Australian leukaemia and lymphoma group (ALLG) trial of thalidomide and alternate day prednisone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLGMM6) [abstract]. Blood2006;108:Abstract 58.
)| false
BarlogieB, KyleRA, AndersonKC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol2006;24:929–936.
BarlogieBKyleRAAndersonKC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol2006;24:929–936.
)| false
RichardsonP, SonneveldP, SchusterM. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood2007;110:3557–3560.
RichardsonPSonneveldPSchusterM. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood2007;110:3557–3560.
)| false
JagannathS, RichardsonPG, SonneveldP. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia2007;21:151–157.
JagannathSRichardsonPGSonneveldP. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia2007;21:151–157.
)| false
OrlowskiRZ, NaglerA, SonneveldP. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol2007;25:3892–3901.
OrlowskiRZNaglerASonneveldP. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol2007;25:3892–3901.
)| false
RichardsonP, JagannathS, HusseinM. A muticenter, single arm, open label study to evaluate the efficacy and safety of single agent lenalidomide in patients with relapsed and refractory multiple myeloma [abstract]. Blood2005;106:Abstract 2550.
RichardsonPJagannathSHusseinM. A muticenter, single arm, open label study to evaluate the efficacy and safety of single agent lenalidomide in patients with relapsed and refractory multiple myeloma [abstract]. Blood2005;106:Abstract 2550.
)| false
LeeCK, BarlogieB, MunshiN. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol2003;21:2732–2739.
LeeCKBarlogieBMunshiN. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol2003;21:2732–2739.
)| false
MohtyM, AttalM, MaritG. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Society Francaise de Greffe de Moelle et Therapie Cellulairs (SFGM-TC). Bone Marrow Transplant2005;35:165–169.
MohtyMAttalMMaritG. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Society Francaise de Greffe de Moelle et Therapie Cellulairs (SFGM-TC). Bone Marrow Transplant2005;35:165–169.
)| false
KnopS, StrakaC, HaenM. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica2005;90:1287–1288.
KnopSStrakaCHaenM. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica2005;90:1287–1288.
)| false
RichardsonP, JagannathS, AviganDE. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract]. Blood2006;108:Abstract 405.
RichardsonPJagannathSAviganDE. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract]. Blood2006;108:Abstract 405.
)| false
AndersonKC, JagannathS, JakubowiakA. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 8545.
AndersonKCJagannathSJakubowiakA. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 8545.
)| false
IkhlaqueN, SeshadriV, KathulaS, BaumannMA. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol2006;81:420–422.
IkhlaqueNSeshadriVKathulaSBaumannMA. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol2006;81:420–422.
)| false
BazR, LiL, Kottke-MarchantK. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc2005;80:1568–1574.
BazRLiLKottke-MarchantK. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc2005;80:1568–1574.
)| false
BerensonJR, LichtensteinA, PorterL. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med1996;334:488–493.
BerensonJRLichtensteinAPorterL. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med1996;334:488–493.
)| false
MajorP, LortholaryA, HonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558–567.
MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558–567.
)| false
BloomfieldDJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol1998;16:1218–1225.
BloomfieldDJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol1998;16:1218–1225.
)| false
KyleRA, YeeGC, SomerfieldMR. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol2007;25:2464–2472.
KyleRAYeeGCSomerfieldMR. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol2007;25:2464–2472.
)| false
ZervasK, VerrouE, TeleioudisZ. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol2006;134:620–623.
ZervasKVerrouETeleioudisZ. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol2006;134:620–623.
)| false
LindsleyH, TellerD, NoonanB. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med1973;54:682–688.
LindsleyHTellerDNoonanB. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med1973;54:682–688.
)| false
OsterborgA, BoogaertsMA, CiminoR. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—a randomized multicenter study. Blood1996;87:2675–682.
OsterborgABoogaertsMACiminoR. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—a randomized multicenter study. Blood1996;87:2675–682.
)| false
Chanan-KhanA, SonneveldP, SchusterMW. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol2008;26:4784–4790.
Chanan-KhanASonneveldPSchusterMW. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol2008;26:4784–4790.
)| false
SkinnerM, SanchorawalaV, SeldinDC. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med2004;140:85–93.
SkinnerMSanchorawalaVSeldinDC. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med2004;140:85–93.
)| false
DispenzieriA, KyleRA, LacyMQ. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: a case control study. Blood2004;103:3960–3963.
DispenzieriAKyleRALacyMQ. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: a case control study. Blood2004;103:3960–3963.
)| false
PalladiniG, PerfettiV, ObiciL. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood2004;103:2936–2938.
PalladiniGPerfettiVObiciL. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood2004;103:2936–2938.
)| false
DhodapkarMV, HusseinMA, RasmussenE. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood2004;104:3520–3526.
DhodapkarMVHusseinMARasmussenE. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood2004;104:3520–3526.
)| false
DispenzieriA, LacyMQ, ZeldenrustSR. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood2007;109:465–470.
DispenzieriALacyMQZeldenrustSR. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood2007;109:465–470.
)| false
SanchorawalaV, WrightDG, RosenzweigM. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood2007;109:492–496.
SanchorawalaVWrightDGRosenzweigM. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood2007;109:492–496.
)| false
WechalekarAD, LachmannHJ, OfferM. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica2008;93:295–298.
WechalekarADLachmannHJOfferM. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica2008;93:295–298.
)| false
ChenCI, KouroukisCT, WhiteD. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:1570–1575.
ChenCIKouroukisCTWhiteD. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:1570–1575.
)| false
GertzMA, AnagnostopoulosA, AndersonKC. Treatment recommendations in Waldenström’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström’s Macroglobulinemia. Semin Oncol2003;30:121–126.
GertzMAAnagnostopoulosAAndersonKC. Treatment recommendations in Waldenström’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström’s Macroglobulinemia. Semin Oncol2003;30:121–126.
)| false
DimopoulosMA, GertzMA, KastritisE. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol2009;27:120–126.
DimopoulosMAGertzMAKastritisE. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol2009;27:120–126.
)| false
ForanJM, RohatinerAZ, CoiffierB. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol1999;17:546–553.
ForanJMRohatinerAZCoiffierB. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol1999;17:546–553.
)| false